Liraglutide in type 2 diabetes: From pharmacological development to clinical practice

Acta Biomedica de l'Ateneo Parmense

Volumn 80, Issue 2, 2009, Pages 93-101

  Rossi, Maria Chiara ^a   Nicolucci, Antonio ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Incretin mimetics; Liraglutide; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ADD ON THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS; METABOLIC REGULATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; DRUG SCREENING; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; TREATMENT OUTCOME;

EID: 73349127491     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
3. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
4. Rossi MC, Nicolucci A, Arcangeli A, Cimino A, De Bigon-tina G, Giorda C et al. Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care 2008; 31: 2166-8.
5. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care 2001; 24: 1815-20.
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
7. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-5.
8. Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007; 30: 807-12.
9. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-42.
10. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-54.
11. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
12. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 2007; 23: 933-44.
13. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin En-docrinol Metab 2003; 88: 2706-13.
14. Triplitt C, McGill JB, Porte D Jr, Conner CS. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm 2007; 13: S2-16.
15. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
16. Nicolucci A, Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008; 79: 184-91.
17. Amori RE, Lau J, Pittas AG. Efficacy and safety of incre-tin therapy in Type 2 Diabetes systematic review and meta-analysis. JAMA 2007; 298: 194-206.
18. TM) trial. Expert Rev Endocrinol Metab 2009; 4: 119-29.
19. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tole-rability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
20. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-9.
21. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009; 297: 137-40.
22. U.S. Food and Drug Administration. Information for healthcare professionals. Exenatide (Byetta). Available at the website http://www.fda.gov/cder/drug/InfoSheets/ HCP/exenatide2008HCP.htm
23. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B. Glu-cagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50: 1562-70.
24. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4600-5.
25. Madsbad S. Smithz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long acting glucagon-like peptide 1 analog liraglu-tide (NNN2211): a 12 week, double blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-342.
26. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Effects of lira-glutide (NN2211), a long-acting GLP-1 analogue, on gly-caemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005; 22: 1016-23.
27. Harder H, Nielsen L, Tu DT, Astrup A. The effect of lira-glutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915-21.
28. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-10.
29. Garber A, Henry R, Ratner R, et al. Liraglutide versus gli-mepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81.
30. Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Diabetes 2009; 58 (suppl. 1): 162-OR.
31. Marre M, Shaw J, Brandle M, et al. Liraglutide added to a sulphonylurea (SU) offers significantly better glycaemic control and favourable weight change compared with rosi-glitazone and SU combination therapy in T2D. Diabetolo-gia 2008; 51 (Suppl. 1): P897.
32. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 3: 84-90.
33. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mel-litus (LEAD-4 Met+TZD). Diabetes Care 2009 [in press].
34. Russel-Jones D, Vaag A, Schmitz O, et al. Significantly better glycaemic control/ weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as addon to metformin + sulphonylurea in type 2 diabetes. Diabe-tologia 2008; 51 (Suppl. 1): OP148.
35. Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; in press.
36. Buse J, Sesti G, Schmidt WE, et al. Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. Diabetes 2009; 58 (suppl. 1): 591.
37. Zinman B, Buse J, Falahati A, Moses A, Gough S. Liraglu-tide more effectively achieves a composite endpoint for A1c, SBP and weight change than other diabetes therapies. Diabetes 2009; 58 (suppl. 1): 537.
38. Nauck MA, Pratley RE, Falahati A, Brett J, Holst JJ. Adding liraglutide to existing therapy rather than substituting it for existing therapy produces greater improvement in gly-cemic control: evidence from a meta-analysis. Diabetes 2009; 58 (suppl. 1): 459.
39. Fonseca V, Madsbad S, Falahati A, Zychma M, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic blood pressure - a meta-analysis of six clinical trials (LEAD). Diabetes 2009; 58 (suppl. 1): 545.
40. Matthews DR, Falahati A, Toft AD, Meier J. Liraglutide improves glycemic control significantly more than glimepi-ride in patients with higher baseline beta-cell function. Diabetes 2009; 58 (suppl. 1): 2064O.
41. Matthews DR, Marre M, Le Thi TD, et al. Liraglutide, a human GLP-1 analogue, significantly improves beta-cell function in subjects with type 2 diabetes. Diabetologia 2008; 51 (Suppl. 1): P892
42. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055-61
43. Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008; 40: 593-60.
44. Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like pep-tide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129-31.
45. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glu-cagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reerfusion. Circulation 2004; 109: 962-5.
46. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-9.
47. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-51.
48. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53: 501-10.
49. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-83.